FindTrial
Sign In

OPTI-TREX - Dose-adjustment of enoxaparin by a bayesian pharmacological approach in pediatric renal transplant recipients

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-513650-30-00
Acronym
APHP180617
Enrollment
50
Registered
2024-07-05
Start date
2023-06-28
Completion date
2025-09-01
Last updated
2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allograft vascular thrombosis

Brief summary

Anti-Xa activity within the target range (i.e., success defined by an anti-Xa activity ≥0.3 IU/mL and ≤0.5 IU/mL) 28-30 hours after initiation of treatment.

Interventions

DRUGENOXAPARIN

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Anti-Xa activity within the target range (i.e., success defined by an anti-Xa activity ≥0.3 IU/mL and ≤0.5 IU/mL) 28-30 hours after initiation of treatment.—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026